{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:29:25Z","timestamp":1791404965542,"version":"4.3.3"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11102-024-01391-2","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T08:01:51Z","timestamp":1714982511000},"page":"778-788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes"],"prefix":"10.1007","volume":"27","author":[{"given":"Amit","family":"Akirov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Rudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"1391_CR1","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S (2024) Hypopituitarism. Lancet, In press","DOI":"10.1016\/S0140-6736(24)00342-8"},{"key":"1391_CR2","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888\u20133921. https:\/\/doi.org\/10.1210\/jc.2016-2118","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1046\/j.1365-2265.2001.01406.x","volume":"55","author":"M Regal","year":"2001","unstructured":"Regal M, Ramo P\u00c2, Sierra J\u00c2M, Garc\u00f5\u00c2a-Mayor RV (2001) Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 55:735\u2013740","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1391_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5114\/reum\/170244","volume":"61","author":"A Wydra","year":"2023","unstructured":"Wydra A, Czajka-Oraniec I, Wydra J, Zgliczy\u0144ski W (2023) The influence of growth hormone deficiency on bone health and metabolism. Reumatologia 61:239\u2013247. https:\/\/doi.org\/10.5114\/reum\/170244","journal-title":"Reumatologia"},{"key":"1391_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/er.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39:440\u2013488. https:\/\/doi.org\/10.1210\/er.2018-00005","journal-title":"Endocr Rev"},{"key":"1391_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/EJE-10-0125","volume":"163","author":"G Mazziotti","year":"2010","unstructured":"Mazziotti G, Porcelli T, Bianchi A et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15\u201320. https:\/\/doi.org\/10.1530\/EJE-10-0125","journal-title":"Eur J Endocrinol"},{"key":"1391_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1530\/EJE-14-0097","volume":"170","author":"G Mazziotti","year":"2014","unstructured":"Mazziotti G, Mormando M, Cristiano A et al (2014) Association between L-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol 170:893\u2013899. https:\/\/doi.org\/10.1530\/EJE-14-0097","journal-title":"Eur J Endocrinol"},{"key":"1391_CR8","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1210\/clinem\/dgad493","volume":"109","author":"S Chiloiro","year":"2023","unstructured":"Chiloiro S, Frara S, Gagliardi I et al (2023) Cholecalciferol use is associated with a decreased risk of incident morphometric vertebral fractures in acromegaly. J Clin Endocrinol Metab 109:e58\u2013e68. https:\/\/doi.org\/10.1210\/clinem\/dgad493","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-002-1345-4","author":"P Ammann","year":"2003","unstructured":"Ammann P, Rizzoli R (2003) Bone strength and its determinants. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-002-1345-4","journal-title":"Osteoporos Int"},{"key":"1391_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","volume":"5","author":"R Eastell","year":"2017","unstructured":"Eastell R, Szulc P (2017) Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 5:908\u2013923. https:\/\/doi.org\/10.1016\/S2213-8587(17)30184-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1391_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tem.2023.01.006","volume":"34","author":"MM Uygur","year":"2023","unstructured":"Uygur MM, Frara S, di Filippo L, Giustina A (2023) New tools for bone health assessment in secreting pituitary adenomas. Trends Endocrinol Metab 34:231\u2013242. https:\/\/doi.org\/10.1016\/j.tem.2023.01.006","journal-title":"Trends Endocrinol Metab"},{"key":"1391_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2213-8587(18)30308-5","volume":"7","author":"EJ Samelson","year":"2019","unstructured":"Samelson EJ, Broe KE, Xu H et al (2019) Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the bone microarchitecture international consortium (BoMIC): a prospective study. Lancet Diabetes Endocrinol 7:34\u201343. https:\/\/doi.org\/10.1016\/S2213-8587(18)30308-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1391_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1210\/er.2007-0036","volume":"29","author":"A Giustina","year":"2008","unstructured":"Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535\u2013559","journal-title":"Endocr Rev"},{"key":"1391_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1530\/eje.0.1370240","volume":"137","author":"T Ros\u00e9n","year":"1997","unstructured":"Ros\u00e9n T, Wilhelmsen L, Landin-Wilhelmsen K et al (1997) Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137:240\u2013245","journal-title":"Eur J Endocrinol"},{"key":"1391_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41574-022-00649-8","volume":"18","author":"G Mazziotti","year":"2022","unstructured":"Mazziotti G, Lania AG, Canalis E (2022) Skeletal disorders associated with the growth hormone\u2013insulin-like growth factor 1 axis. Nat Rev Endocrinol 18:353\u2013365. https:\/\/doi.org\/10.1038\/s41574-022-00649-8","journal-title":"Nat Rev Endocrinol"},{"key":"1391_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/jcb.22322","volume":"108","author":"E Canalis","year":"2009","unstructured":"Canalis E (2009) Growth factor control of bone mass. J Cell Biochem 108:769\u2013777. https:\/\/doi.org\/10.1002\/jcb.22322","journal-title":"J Cell Biochem"},{"key":"1391_CR17","first-page":"55","volume":"19","author":"C Ohlsson","year":"1998","unstructured":"Ohlsson C, Bengtsson B-\u00c5, Isaksson OGP et al (1998) Growth hormone and bone*. Endocr Rev 19:55\u201379","journal-title":"Endocr Rev"},{"key":"1391_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1530\/EJE-13-0280","volume":"169","author":"KCJ Yuen","year":"2013","unstructured":"Yuen KCJ, Koltowska-Haggstrom M, Cook DM et al (2013) Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction. Eur J Endocrinol 169:511\u2013519. https:\/\/doi.org\/10.1530\/EJE-13-0280","journal-title":"Eur J Endocrinol"},{"key":"1391_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2265.2003.01949.x","volume":"60","author":"GI Baroncelli","year":"2004","unstructured":"Baroncelli GI, Bertelloni S, Sodini F, Saggese G (2004) Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf) 60:175\u2013184. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01949.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1391_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1530\/EJE-12-0070","volume":"167","author":"NA Tritos","year":"2012","unstructured":"Tritos NA, Hamrahian AH, King D et al (2012) A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: A KIMS database analysis. Eur J Endocrinol 167:343\u2013351. https:\/\/doi.org\/10.1530\/EJE-12-0070","journal-title":"Eur J Endocrinol"},{"key":"1391_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000506229","volume":"92","author":"TG Baer","year":"2020","unstructured":"Baer TG, Agarwal S, Chen S et al (2020) Deficits in bone geometry in growth hormone-deficient prepubertal boys revealed by high-resolution peripheral quantitative computed tomography. Horm Res Paediatr 92:293\u2013301. https:\/\/doi.org\/10.1159\/000506229","journal-title":"Horm Res Paediatr"},{"key":"1391_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/EJE-18-0711","volume":"180","author":"H Yang","year":"2019","unstructured":"Yang H, Yan K, Xu Y et al (2019) Bone microarchitecture and volumetric bone density impairment in young male adults with childhood-onset growth hormone deficiency. Eur J Endocrinol 180:145\u2013153. https:\/\/doi.org\/10.1530\/EJE-18-0711","journal-title":"Eur J Endocrinol"},{"key":"1391_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","volume":"52","author":"G Mazziotti","year":"2016","unstructured":"Mazziotti G, Doga M, Frara S et al (2016) Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52:103\u2013110. https:\/\/doi.org\/10.1007\/s12020-015-0738-z","journal-title":"Endocrine"},{"key":"1391_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1359\/jbmr.2002.17.6.1081","volume":"17","author":"M Bex","year":"2002","unstructured":"Bex M, Abs R, Maiter D et al (2002) The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: A 2-year open randomized controlled multicenter trial. J Bone Miner Res 17:1081\u20131094. https:\/\/doi.org\/10.1359\/jbmr.2002.17.6.1081","journal-title":"J Bone Miner Res"},{"key":"1391_CR25","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2013-3921","volume":"99","author":"M Barake","year":"2014","unstructured":"Barake M, Klibanski A, Tritos NA (2014) Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99:852\u2013860. https:\/\/doi.org\/10.1210\/jc.2013-3921","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/cen.12493","volume":"81","author":"NM Appelman-Dijkstra","year":"2014","unstructured":"Appelman-Dijkstra NM, Claessen KMJA, Hamdy NAT et al (2014) Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the leiden cohort study. Clin Endocrinol (Oxf) 81:727\u2013735. https:\/\/doi.org\/10.1111\/cen.12493","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1391_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1530\/EJE-08-0436","volume":"160","author":"GS Conway","year":"2009","unstructured":"Conway GS, Szarras-Czapnik M, Racz K et al (2009) Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 160:899\u2013907. https:\/\/doi.org\/10.1530\/EJE-08-0436","journal-title":"Eur J Endocrinol"},{"key":"1391_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1159\/000223422","volume":"71","author":"AM Boot","year":"2009","unstructured":"Boot AM, Van Der Sluis IM, Krenning EP, De Muinck K-S (2009) Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency. Horm Res 71:364\u2013371. https:\/\/doi.org\/10.1159\/000223422","journal-title":"Horm Res"},{"key":"1391_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1359\/jbmr.060112","volume":"21","author":"G Mazziotti","year":"2006","unstructured":"Mazziotti G, Bianchi A, Bonadonna S et al (2006) Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: Influence of GH replacement therapy. J Bone Miner Res 21:520\u2013528. https:\/\/doi.org\/10.1359\/jbmr.060112","journal-title":"J Bone Miner Res"},{"key":"1391_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1530\/EJE-11-1072","volume":"166","author":"M Elbornsson","year":"2012","unstructured":"Elbornsson M, G\u00f6therstr\u00f6m G, Bos\u00e6us I et al (2012) Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166:787\u2013795. https:\/\/doi.org\/10.1530\/EJE-11-1072","journal-title":"Eur J Endocrinol"},{"key":"1391_CR31","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s12020-021-02835-6","volume":"74","author":"A Rossini","year":"2021","unstructured":"Rossini A, Lanzi R, Galeone C et al (2021) Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy. Endocrine 74:666\u2013675. https:\/\/doi.org\/10.1007\/s12020-021-02835-6","journal-title":"Endocrine"},{"key":"1391_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S2213-8587(15)00098-4","volume":"3","author":"D Mo","year":"2015","unstructured":"Mo D, Fleseriu M, Qi R et al (2015) Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3:331\u2013338. https:\/\/doi.org\/10.1016\/S2213-8587(15)00098-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1391_CR33","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM et al (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2265.2004.02021.x","volume":"60","author":"NR Biermasz","year":"2004","unstructured":"Biermasz NR, Hamdy NAT, Pereira AM et al (2004) Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol (Oxf) 60:568\u2013575. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02021.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1391_CR35","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1210\/jcem.86.7.7669","volume":"86","author":"NR Biermasz","year":"2001","unstructured":"Biermasz NR, Hamdy NAT, Janssen YJH, Roelfsema F (2001) Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J Clin Endocrinol Metab 86:3079\u20133085","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40618-014-0169-3","volume":"37","author":"B Meczekalski","year":"2014","unstructured":"Meczekalski B, Katulski K, Czyzyk A et al (2014) Functional hypothalamic amenorrhea and its influence on women\u2019s health. Acad Psychiatry 37:1049\u20131056. https:\/\/doi.org\/10.1007\/s40618-014-0169-3","journal-title":"Acad Psychiatry"},{"key":"1391_CR37","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1055\/s-0037-1603581","volume":"35","author":"CL Shufelt","year":"2017","unstructured":"Shufelt CL, Torbati T, Dutra E (2017) Hypothalamic amenorrhea and the long-term health consequences. Semin Reprod Med 35:256\u2013262. https:\/\/doi.org\/10.1055\/s-0037-1603581","journal-title":"Semin Reprod Med"},{"key":"1391_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/13697137.2020.1767567","volume":"23","author":"I Ilovayskaya","year":"2020","unstructured":"Ilovayskaya I, Zektser V, Lazebnik L (2020) Factors of mineral homeostasis impairment and bone mineral density loss in women with central hypogonadism. Climacteric 23:597\u2013602. https:\/\/doi.org\/10.1080\/13697137.2020.1767567","journal-title":"Climacteric"},{"key":"1391_CR39","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","volume":"23","author":"S Khosla","year":"2012","unstructured":"Khosla S, Oursler MJ, Monroe DG (2012) Estrogen and the skeleton. Trends Endocrinol Metab 23:576\u2013581. https:\/\/doi.org\/10.1016\/j.tem.2012.03.008","journal-title":"Trends Endocrinol Metab"},{"key":"1391_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4183\/aeb.2022.355","volume":"18","author":"C Ampatzis","year":"2022","unstructured":"Ampatzis C, Zervoudis S, Iatrakis G, Mastorakos G (2022) Effect of oral contraceptives on bone mineral density. Acta Endocrinol (Copenh) 18:355\u2013360. https:\/\/doi.org\/10.4183\/aeb.2022.355","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1391_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12020-018-1604-6","volume":"61","author":"N Tahani","year":"2018","unstructured":"Tahani N, Nieddu L, Prossomariti G et al (2018) Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter syndrome. Endocrine 61:327\u2013335. https:\/\/doi.org\/10.1007\/s12020-018-1604-6","journal-title":"Endocrine"},{"key":"1391_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s40618-014-0125-2","volume":"37","author":"M Pedrazzoni","year":"2014","unstructured":"Pedrazzoni M, Casola A, Verzicco I et al (2014) Longitudinal changes of trabecular bone score after estrogen deprivation: effect of menopause and aromatase inhibition. J Endocrinol Invest 37:871\u2013874. https:\/\/doi.org\/10.1007\/s40618-014-0125-2","journal-title":"J Endocrinol Invest"},{"key":"1391_CR43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","volume":"177","author":"PJ Snyder","year":"2017","unstructured":"Snyder PJ, Kopperdahl DL, Stephens-Shields AJ et al (2017) Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone a controlled clinical trial. JAMA Intern Med 177:471\u2013479. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9539","journal-title":"JAMA Intern Med"},{"key":"1391_CR44","doi-asserted-by":"publisher","first-page":"E3312","DOI":"10.1210\/clinem\/dgab169","volume":"106","author":"A Ostertag","year":"2021","unstructured":"Ostertag A, Papadakis GE, Collet C et al (2021) Compromised volumetric bone density and microarchitecture in men with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 106:E3312\u2013E3326. https:\/\/doi.org\/10.1210\/clinem\/dgab169","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR45","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/andr.12604","volume":"7","author":"L Antonio","year":"2019","unstructured":"Antonio L, Caerels S, Jardi F et al (2019) Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects. Andrology 7:302\u2013306. https:\/\/doi.org\/10.1111\/andr.12604","journal-title":"Andrology"},{"key":"1391_CR46","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1210\/jc.2004-0897","volume":"89","author":"M Schubert","year":"2004","unstructured":"Schubert M, Minnemann T, H\u00fcbler D et al (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429\u20135434. https:\/\/doi.org\/10.1210\/jc.2004-0897","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR47","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.eprac.2021.12.013","volume":"28","author":"B-na Zhou","year":"2022","unstructured":"Zhou B-na, Hu J, Sun L et al (2022) Effects of bisphosphonates on bone of osteoporotic men with different androgen levels: a case-control study. Endocr Pract 28:250\u2013256. https:\/\/doi.org\/10.1016\/j.eprac.2021.12.013","journal-title":"Endocr Pract"},{"key":"1391_CR48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/cen.13901","volume":"90","author":"CM Jankowski","year":"2019","unstructured":"Jankowski CM, Wolfe P, Schmiege SJ et al (2019) Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: a pooled analysis of four clinical trials. Clin Endocrinol (Oxf) 90:293\u2013300. https:\/\/doi.org\/10.1111\/cen.13901","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1391_CR49","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1210\/jc.2010-2888","volume":"96","author":"SR Davis","year":"2011","unstructured":"Davis SR, Panjari M, Stanczyk FZ (2011) DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 96:1642\u20131653. https:\/\/doi.org\/10.1210\/jc.2010-2888","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR50","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1210\/jc.2007-2614","volume":"93","author":"CM Jankowski","year":"2008","unstructured":"Jankowski CM, Gozansky WS, Kittelson JM et al (2008) Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab 93:4767\u20134773. https:\/\/doi.org\/10.1210\/jc.2007-2614","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11102-021-01182-z","volume":"25","author":"F Amereller","year":"2022","unstructured":"Amereller F, Deutschbein T, Joshi M et al (2022) Differences between immunotherapy-induced and primary hypophysitis\u2014a multicenter retrospective study. Pituitary 25:152\u2013158. https:\/\/doi.org\/10.1007\/s11102-021-01182-z","journal-title":"Pituitary"},{"key":"1391_CR52","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1530\/EJE-08-0880","volume":"160","author":"K L\u00f8vas","year":"2009","unstructured":"L\u00f8vas K, Gjesdal CG, Christensen M et al (2009) Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: Effects on bone. Eur J Endocrinol 160:993\u20131002. https:\/\/doi.org\/10.1530\/EJE-08-0880","journal-title":"Eur J Endocrinol"},{"key":"1391_CR53","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1210\/jcem.86.12.8066","volume":"86","author":"E Canalis","year":"2001","unstructured":"Canalis E, Giustina A (2001) Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 86:5681\u20135685","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR54","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1210\/jc.2010-2662","volume":"96","author":"NA Tritos","year":"2011","unstructured":"Tritos NA, Greenspan SL, King D et al (2011) Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis. J Clin Endocrinol Metab 96:1516\u20131523. https:\/\/doi.org\/10.1210\/jc.2010-2662","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12020-021-02723-z","volume":"74","author":"L Li","year":"2021","unstructured":"Li L, Bensing S, Falhammar H (2021) Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis. Endocrine 74:29\u201337. https:\/\/doi.org\/10.1007\/s12020-021-02723-z","journal-title":"Endocrine"},{"key":"1391_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2011-2036","volume":"97","author":"KR Koetz","year":"2012","unstructured":"Koetz KR, Ventz M, Diederich S, Quinkler M (2012) Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 97:85\u201392. https:\/\/doi.org\/10.1210\/jc.2011-2036","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR57","doi-asserted-by":"publisher","first-page":"R231","DOI":"10.1530\/EJE-17-0154","volume":"177","author":"G Mazziotti","year":"2017","unstructured":"Mazziotti G, Formenti AM, Frara S et al (2017) Risk of overtreatment of patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol 177:R231\u2013R248. https:\/\/doi.org\/10.1530\/EJE-17-0154","journal-title":"Eur J Endocrinol"},{"key":"1391_CR58","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00223-008-9124-7","volume":"82","author":"P Vestergaard","year":"2008","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2008) Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 82:249\u2013257. https:\/\/doi.org\/10.1007\/s00223-008-9124-7","journal-title":"Calcif Tissue Int"},{"key":"1391_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-120-3-199402010-00005","volume":"120","author":"PM Zelissen","year":"1994","unstructured":"Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA (1994) Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120:207\u2013210","journal-title":"Ann Intern Med"},{"key":"1391_CR60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-15-1096","volume":"174","author":"J Schulz","year":"2016","unstructured":"Schulz J, Frey KR, Cooper MS et al (2016) Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur J Endocrinol 174:531\u2013538. https:\/\/doi.org\/10.1530\/EJE-15-1096","journal-title":"Eur J Endocrinol"},{"key":"1391_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4158\/EP161428.OR","volume":"23","author":"A Al Nofal","year":"2017","unstructured":"Al Nofal A, Bancos I, Benkhadra K et al (2017) Glucocorticoid replacement regimens in chronic adrenal insufficiency: a systematic review and meta-analysis. Endocr Pract 23:17\u201331. https:\/\/doi.org\/10.4158\/EP161428.OR","journal-title":"Endocr Pract"},{"key":"1391_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrendo.2013.5","volume":"9","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9:265\u2013276. https:\/\/doi.org\/10.1038\/nrendo.2013.5","journal-title":"Nat Rev Endocrinol"},{"key":"1391_CR63","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/cen.13554","volume":"88","author":"V Guarnotta","year":"2018","unstructured":"Guarnotta V, Ciresi A, Pillitteri G, Giordano C (2018) Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin Endocrinol (Oxf) 88:665\u2013672. https:\/\/doi.org\/10.1111\/cen.13554","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1391_CR64","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1530\/EC-19-0176","volume":"8","author":"V Guarnotta","year":"2019","unstructured":"Guarnotta V, Di Stefano C, Santoro A et al (2019) Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr Connect 8:853\u2013862. https:\/\/doi.org\/10.1530\/EC-19-0176","journal-title":"Endocr Connect"},{"key":"1391_CR65","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/EJE-14-1114","volume":"172","author":"M Quinkler","year":"2015","unstructured":"Quinkler M, Nilsen RM, Zopf K et al (2015) Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 172:619\u2013626. https:\/\/doi.org\/10.1530\/EJE-14-1114","journal-title":"Eur J Endocrinol"},{"key":"1391_CR66","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12020-017-1512-1","volume":"60","author":"S Frara","year":"2018","unstructured":"Frara S, Chiloiro S, Porcelli T et al (2018) Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 60:528\u2013531. https:\/\/doi.org\/10.1007\/s12020-017-1512-1","journal-title":"Endocrine"},{"key":"1391_CR67","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad151","author":"V Hasenmajer","year":"2024","unstructured":"Hasenmajer V, Ferrari D, De Alcubierre D et al (2024) Effects of dual-release hydrocortisone on bone metabolism in primary and secondary adrenal insufficiency: A 6-year study. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvad151","journal-title":"J Endocr Soc"},{"key":"1391_CR68","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/er.2015-1106","volume":"37","author":"JH Duncan Bassett","year":"2016","unstructured":"Duncan Bassett JH, Williams GR (2016) Role of thyroid hormones in skeletal development and bone maintenance. Endocr Rev 37:135\u2013187. https:\/\/doi.org\/10.1210\/er.2015-1106","journal-title":"Endocr Rev"},{"key":"1391_CR69","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2018-0039","author":"K Tsevis","year":"2018","unstructured":"Tsevis K, Trakakis E, Pergialiotis V et al (2018) The influence of thyroid disorders on bone density and biochemical markers of bone metabolism. Horm Mol Biol Clin Investig. https:\/\/doi.org\/10.1515\/hmbci-2018-0039","journal-title":"Horm Mol Biol Clin Investig"},{"key":"1391_CR70","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/jbmr.2416","volume":"30","author":"B Abrahamsen","year":"2015","unstructured":"Abrahamsen B, J\u00f8rgensen HL, Laulund AS et al (2015) The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis. J Bone Miner Res 30:898\u2013905. https:\/\/doi.org\/10.1002\/jbmr.2416","journal-title":"J Bone Miner Res"},{"key":"1391_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3961\/jpmph.2014.47.1.36","volume":"47","author":"YJ Ko","year":"2014","unstructured":"Ko YJ, Kim JY, Lee J et al (2014) Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. J Prev Med Public Health 47:36\u201346. https:\/\/doi.org\/10.3961\/jpmph.2014.47.1.36","journal-title":"J Prev Med Public Health"},{"key":"1391_CR72","doi-asserted-by":"publisher","first-page":"101453","DOI":"10.1016\/j.jocd.2023.101453","volume":"27","author":"L Nagendra","year":"2024","unstructured":"Nagendra L, Dutta D, Mondal S et al (2024) Hyperprolactinemia due to prolactinoma has an adverse impact on bone health with predominant impact on trabecular bone: a systematic review and meta-analysis. J Clin Densitom 27:101453. https:\/\/doi.org\/10.1016\/j.jocd.2023.101453","journal-title":"J Clin Densitom"},{"key":"1391_CR73","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1046\/j.1365-2265.2003.01916.x","volume":"59","author":"A Mukherjee","year":"2003","unstructured":"Mukherjee A, Murray RD, Columb B et al (2003) Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis. Clin Endocrinol (Oxf) 59:743\u2013748. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01916.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1391_CR74","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0006-291X(02)02009-0","volume":"297","author":"S Colucci","year":"2002","unstructured":"Colucci S, Colaianni G, Mori G et al (2002) Human osteoclasts express oxytocin receptor. Biochem Biophys Res Commun 297:442\u2013445","journal-title":"Biochem Biophys Res Commun"},{"key":"1391_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168551","author":"V Breuil","year":"2021","unstructured":"Breuil V, Trojani MC, Ez-Zoubir A (2021) Oxytocin and bone: review and perspectives. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22168551","journal-title":"Int J Mol Sci"},{"key":"1391_CR76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000506638","volume":"111","author":"A Aulinas","year":"2020","unstructured":"Aulinas A, Guarda FJ, Yu EW et al (2020) Lower oxytocin levels are associated with lower bone mineral density and less favorable hip geometry in hypopituitary men. Neuroendocrinology 111:87\u201398. https:\/\/doi.org\/10.1159\/000506638","journal-title":"Neuroendocrinology"},{"key":"1391_CR77","first-page":"437","volume":"15","author":"C Cooper","year":"1985","unstructured":"Cooper C, Malik KU (1985) Mechanism of action of vasoactive hormones on prostaglandin synthesis in the kidney. Adv Prostaglandin Thromboxane Leukot Res 15:437\u2013440","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"key":"1391_CR78","doi-asserted-by":"publisher","first-page":"18644","DOI":"10.1073\/pnas.1318257110","volume":"110","author":"R Tamma","year":"2013","unstructured":"Tamma R, Sun L, Cuscito C et al (2013) Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci USA 110:18644\u201318649. https:\/\/doi.org\/10.1073\/pnas.1318257110","journal-title":"Proc Natl Acad Sci USA"},{"key":"1391_CR79","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1359\/jbmr.090827","volume":"25","author":"JG Verbalis","year":"2010","unstructured":"Verbalis JG, Barsony J, Sugimura Y et al (2010) Hyponatremia-induced osteoporosis. J Bone Miner Res 25:554\u2013563. https:\/\/doi.org\/10.1359\/jbmr.090827","journal-title":"J Bone Miner Res"},{"key":"1391_CR80","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/jbmr.380","volume":"26","author":"EJ Hoorn","year":"2011","unstructured":"Hoorn EJ, Rivadeneira F, Van Meurs JBJ et al (2011) Mild hyponatremia as a risk factor for fractures: the rotterdam study. J Bone Miner Res 26:1822\u20131828. https:\/\/doi.org\/10.1002\/jbmr.380","journal-title":"J Bone Miner Res"},{"key":"1391_CR81","first-page":"2275","volume":"83","author":"R Pivonello","year":"1998","unstructured":"Pivonello R, Colao A, Di Somma C et al (1998) Impairment of bone status in patients with central diabetes insipidus*. J Clin Endocrinol Metab 83:2275\u20132280","journal-title":"J Clin Endocrinol Metab"},{"key":"1391_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s41747-021-00242-0","author":"FM Ulivieri","year":"2021","unstructured":"Ulivieri FM, Rinaudo L, Messina C et al (2021) Bone strain index predicts fragility fracture in osteoporotic women: an artificial intelligence-based study. Eur Radiol Exp. https:\/\/doi.org\/10.1186\/s41747-021-00242-0","journal-title":"Eur Radiol Exp"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01391-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T05:34:55Z","timestamp":1733895295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01391-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01391-2","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"29 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MF is on the editorial board of Pituitary. MF has received research support to Oregon Health & Science University as principal investigator from Ascendis and has received occasional scientific consulting fees from Novo Nordisk. Other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}